title: The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.
abstract: Until recently, systemic therapy for gastrointestinal malignancies was restricted to relatively noncancer-specific cytotoxic chemotherapy. Over the last 15 years targeted therapies have become available, most notably bevacizumab in the case of advanced colorectal cancer. Unfortunately, there are no predictive biomarkers to guide the use of this agent. In this review article, we describe the advent of "Precision Medicine" (in part, the use of patient-specific molecular markers to inform treatment) in gastrointestinal cancers: The use of monoclonal antibodies targeting epidermal growth factor receptor in advanced colorectal cancer, and human epidermal growth factor receptor 2-neu in advanced esophagogastric cancer. In both instances, biomarkers help in selecting appropriate patients for such treatment.
authors.affiliation: Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
authors.forename: Danielle
authors.initials: D
authors.lastname: Desautels
authors.affiliation: Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
authors.forename: Craig
authors.initials: C
authors.lastname: Harlos
authors.affiliation: Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3E 0V9, Canada ; Department of Medical Oncology and Hematology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada.
authors.forename: Piotr
authors.initials: P
authors.lastname: Czaykowski
keywords: Colorectal cancer; esophagogastric cancer; precision therapy; targeted therapy